ISIN | LU1178102759 |
---|---|
Valor Number | 26808198 |
Bloomberg Global ID | |
Fund Name | RH&P Global Life Sciences Fund I DIS EUR |
Fund Provider |
RH&PARTNER Investment Funds
Basel, Switzerland Phone: +41 61 378 83 63 E-Mail: info@rh-finanz.ch Web: https://www.rh-finanz.ch |
Fund Provider | RH&PARTNER Investment Funds |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) |
Banque Pictet & Cie SA
Credit Suisse Zürich UBS n/a Vontobel n/a |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Distribution |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 91.20 EUR | 27.03.2025 |
---|---|---|
Previous Price * | 90.87 EUR | 26.03.2025 |
52 Week High * | 100.72 EUR | 08.11.2024 |
52 Week Low * | 83.60 EUR | 19.04.2024 |
NAV * | 91.20 EUR | 27.03.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 58,146,998 | |
Unit/Share Assets *** | 469,336 | |
Trading Information SIX |
YTD Performance | -0.32% |
31.12.2024 - 27.03.2025
31.12.2024 27.03.2025 |
---|---|---|
YTD Performance (in CHF) | +0.94% |
31.12.2024 - 27.03.2025
31.12.2024 27.03.2025 |
1 month | -4.32% |
27.02.2025 - 27.03.2025
27.02.2025 27.03.2025 |
3 months | -1.64% |
27.12.2024 - 27.03.2025
27.12.2024 27.03.2025 |
6 months | -6.21% |
27.09.2024 - 27.03.2025
27.09.2024 27.03.2025 |
1 year | +0.41% |
27.03.2024 - 27.03.2025
27.03.2024 27.03.2025 |
2 years | +1.25% |
27.03.2023 - 27.03.2025
27.03.2023 27.03.2025 |
3 years | -3.35% |
28.03.2022 - 27.03.2025
28.03.2022 27.03.2025 |
5 years | +3.11% |
27.03.2020 - 27.03.2025
27.03.2020 27.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Charles River Laboratories International Inc | 4.53% | |
---|---|---|
Bio-Techne Corp | 4.46% | |
Nektar Therapeutics | 4.36% | |
Illumina Inc | 3.93% | |
Exelixis Inc | 3.87% | |
Alkermes PLC | 3.72% | |
IQVIA Holdings Inc | 3.65% | |
Biogen Inc | 3.59% | |
Amgen Inc | 3.57% | |
Incyte Corp | 3.53% | |
Last data update | 30.04.2021 |
TER *** | 1.72% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.70% |
Ongoing Charges *** | 1.67% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |